SOFINNOVA-PARTNERS
Sofinnova Partners , a leading European life sciences venture capital firm based in Paris, London and Milan, announced today three new investments from the Sofinnova Telethon Fund, its early-stage fund dedicated to investments in rare, genetic diseases. The startups, AAVantgarde Bio , Alia Therapeutics , and Borea Therapeutics , are developing promising new therapies for rare, genetic diseases.
Graziano Seghezzi, Managing Partner at Sofinnova Partners, commented: “These investments mark an important step in our mission to support the excellent scientific research coming out of Italian academic and research centers. They also highlight the exceptional flow of new investment opportunities in Italian biotech, and the important role that venture capital plays in enabling ground-breaking treatments to reach patients suffering from rare, genetic diseases who today have very few therapeutic options.”
The Sofinnova Telethon Fund is the largest fund entirely dedicated to biotechnology in Italy. The team is led by technology transfer specialists Lucia Faccio and Paola Pozzi, Partners at Sofinnova Partners, who are based in the firm’s Milan office.
The three new seed investments, totaling €6M, align with the fund’s investment strategy to seek out and support the best Italian science and the most promising entrepreneurs to develop world-class companies in the field of rare, genetic diseases.
AAVantgarde Bio, based in Milan, is developing gene therapies for inherited retinal disorders. The founder, Professor Alberto Auricchio, is a highly recognized scientist and a pioneer in the field of gene therapy. The company’s technology builds on existing AAV, or adeno-associated virus-based platforms, which are the main viral vector technology used in gene therapy applications. Existing AAV-based platforms have been limited by capacity, and AAVantgarde Bio responds to this challenge by enabling delivery of large genes to tissue and cells in vivo. The company is a spin-off of TIGEM, an international research institute based in Naples that is owned and managed by the Telethon Foundation.
Alia Therapeutics, based in Trento, is developing next generation CRISPR-based medicine for safer on-target in vivo gene editing approaches to the treatment of retinal degeneration. Alia is a spin-off of the University of Trento and was accelerated at BiovelocITA, Italy’s first biotechnology accelerator co-founded in 2015 by Sofinnova Partners and two serial entrepreneurs, Silvano Spinelli and Gabriella Camboni. It is the second company to emerge from the accelerator, following the success of Enthera Pharmaceuticals, another Italian startup that is part of Sofinnova Partners’ portfolio. This round of financing also included participation from BiovelocITA, Indaco Venture Partners, and a group of Italian investors brought together by Banor SIM and Banca Profilo.
Ms. Pozzi, Partner at Sofinnova Partners, board member of AAVantgarde Bio and an investment partner in Alia Therapeutics, commented: “We are delighted to support these innovative biotech startups as they advance promising programs towards preclinical and clinical development. Both companies have highly qualified scientific teams with globally recognized expertise in the field of gene therapy and gene editing. We are confident in the potential of these companies to tackle the limitations of existing therapies and develop treatments to diseases that do not have adequate solutions today.”
Borea Therapeutics, based in Milan, is advancing a new generation of gene therapies that would enable targeting of specific tissues and cells. The company’s innovative technology could enable viral vectors to reach areas like the central nervous system (CNS) and peripheral nervous system (PNS), thus opening the door to new therapeutic options. Borea Therapeutics was co-founded by Professor Paul Heppenstall and the European Molecular Biology Lab (EMBL), an intergovernmental research organization with six research sites throughout Europe, including one in Rome. The company’s research activities are performed in collaboration with Scuola Internazionale Superiore di Studi Avanzati (SISSA), a scientific center of excellence in Trieste.
Ms. Faccio, Partner at Sofinnova Partners and a board member of Borea Therapeutics, commented: “One of the major limitations of gene therapy is the difficulty of selectively targeting specific cells or tissues. Borea Therapeutics’ technology has the potential to pinpoint specific tissues and cells, which would enable the use of lower doses, making treatment safer and more effective for patients. This could be the next breakthrough in gene therapy.”
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply-established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management. For more information, please visit: www.sofinnovapartners.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210630005320/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Chelsea Football Club and FPT Elevate and Expand Partnership to Principal Status22.10.2025 11:12:00 CEST | Press release
Chelsea Football Club and FPT today announce an expansion to their existing partnership, which sees Asia Pacific’s most successful technology solutions provider named as a Principal Partner for the 2025/26 season. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251017778664/en/ As a Principal Partner, FPT will be represented on the sleeves of the Chelsea FC men’s, women’s, and academy kits. The market-leading digital technology solutions provider FPT and Chelsea FC first joined forces earlier this year in a new and innovative collaboration to transform the club’s digital capabilities and enhance the club’s fan engagement, bringing fans from across the world closer to the club. Through several technology workshops at FPT’s innovation campus in Vietnam, Chelsea FC and FPT have identified and built a transformation roadmap that covers Digital Platforms, Customer Engagement, Business Operations, and Emerging Technologies. With a
Paymentology Launches PayCredit to Power Credit Innovation for Digital Banks and Fintechs22.10.2025 10:00:00 CEST | Press release
The new credit solution integrates card issuing and credit ledger management, helping issuers reduce complexity and accelerate time to market. Paymentology, the leading global issuer-processor, has launched PayCredit, an advanced credit ledger platform designed to help financial institutions deliver tailored, feature rich credit products at speed, overcoming the limitations of legacy and core banking systems. Amid rising demand for flexible financial payment tools, credit cards remain a critical instrument for enabling consumer spending, managing cash flow, and deepening customer loyalty. Yet many legacy credit systems lack the flexibility to meet the expectations of today's consumers, who demand a combination of both revolving and instalment credit to help them better manage their money, whilst many modern ledgers are retrofitted from a debit architecture and struggle to provide credit processing. PayCredit was developed from the ground up with credit billing cycles and logic at its c
Infrastructure Capital Advisors Expands its Offerings into European Markets With Launch of Preferred Income UCITS ETF (PFFI) & Declares The Fund’s First Dividend22.10.2025 10:00:00 CEST | Press release
PFFI is now listed on the LSE, Xetra and Borsa Italiana Exchanges and registered in 11 European markets Infrastructure Capital Advisors (“Infrastructure Capital”), a leading provider of investment management solutions designed to meet the needs of income-focused investors, is celebrating the expansion of its offerings into Europe with the launch of the Infrastructure Capital Preferred Income UCITS ETF (PFFI). This actively managed ETF, which was listed in September, seeks to produce diversified income by targeting high yield income investments by predominately focusing on preferred stocks. Today,PFFI is also declaring its first dividend of $0.1335 per share ($1.602 per share on an annualized basis). The dividend will be paid on November 3, 2025 to shareholders of record as of the close of business on October 29, 2025. “We are thrilled to offer investors across a range of global markets the opportunity to benefit from our team’s active management process applied to preferred and income
Locus Robotics Reports Record Growth Achieving 6 Billion Picks in Fastest Time Yet22.10.2025 10:00:00 CEST | Press release
Accelerating adoption, rapid customer ROI, and consecutive record quarters fuel positive market momentum Locus Robotics, the global leader in AI-driven, mobile warehouse automation, today announced its strongest growth over the past two quarters, reflecting accelerating industry adoption of Physical AI, seamlessly fusing intelligent robotics and real-world execution. Driven by surging implementations and faster time-to-value for customers, Locus Robotics recently surpassed 6 billion picks worldwide, with the last billion in just 24 weeks—the fastest pace in its history. “Our growth is driven by our customers’ success,” said Rick Faulk, CEO of Locus Robotics. “Retailers, 3PLs, and healthcare providers are seeing measurable impact faster than ever—scaling productivity in weeks, not months. Staples Canada, for example, hit one million picks just 70 days after going live, proving the immediate ROI our platform delivers.” So far this year, Locus Robotics has seen 30–40% year-over-year volum
Smartstream and ActiveViam Collaborate to Meet Demands for Collateral Optimisation22.10.2025 09:55:00 CEST | Press release
Key Facts Smartstream and ActiveViam have partnered to deliver an integrated solution combining Smartstream’s Smart Collateral with ActiveViam’s Atoti Collateral Optimisation platform. The collaboration enables financial institutions to optimise collateral allocation, reduce reliance on costly liquidity buffers, and achieve immediate return on investment. The modular, high-performance solution supports regulatory compliance (UMR, EMIR, Basel III) and empowers clients to make smarter use of their collateral inventory. Smartstream, the trusted data solutions provider for leading global financial institutions and enterprises, today announces the partnership with ActiveViam, a global provider of advanced data analytics and decision-making solutions for financial services – together the two companies will provide immediate ROI for collateral management optimisation, for clients in treasury and capital markets. This collaboration connects two technologies, Smartstream’s Smart Collateral with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom